Table 1.
N | % | |
---|---|---|
Overall | 24,964 | 100 |
Age at the 1st dose | ||
19–21 | 14,111 | 56.5 |
22–26 | 10,853 | 43.5 |
Region | ||
Midwest | 7,113 | 28.5 |
Northeast | 3,361 | 13.5 |
South | 10,841 | 43.4 |
West | 3,649 | 14.6 |
Provider giving the 1st dose | ||
Obstetrics/gynecology | 12,180 | 48.8 |
Primary care provider | 8,725 | 35.0 |
Adolescent/pediatric provider | 3,295 | 13.2 |
Other | 764 | 3.1 |
Year of the 1st dose | ||
2006 | 1,369 | 5.5 |
2007 | 10,398 | 41.7 |
2008 | 7,929 | 31.8 |
2009 | 5,268 | 21.1 |
Number of doses received | ||
1 | 5,369 | 21.5 |
2 | 5,951 | 23.8 |
3 | 13,477 | 54.0 |
4+ | 167 | 0.7 |
Appropriate interval between doses 1 and 3 | ||
Appropriatea | 8,719 | 34.9 |
Inappropriate | 4,925 | 19.7 |
< 3 doses | 11,320 | 45.3 |
History of cervical dysplasiab | ||
No | 20,847 | 83.5 |
Yes | 4,117 | 16.5 |
Number of women who received tests between months 1 and 37 after the 1st dosec | ||
Pap test | 19,797 | 79.3 |
Median (Q1–Q3) | ||
Days between doses 1 and 2 | 66 (61–94) | |
Days between doses 1 and 3 | 194 (183–231) |
defined as 6–8 months
defined as any woman having a diagnosis for cervical dysplasia (622.10–622.12), abnormal Pap smear (795.00–795.04), cervical malignant neoplasm (180.1, 180.8), carcinoma in situ of cervix uteri (233.1), or having any colposcopy or LEEP between 6 months before and 1 month following the 1st dose.
Well woman exams (ICD-9 code V72.31), Pap tests (CPT codes 88141-88143, 88147, 88148, 88150, 88152-88155, 88164-88167, 88174, 88175; HCPCS codes G0123, G0124, G0141, G0143G0145, G0147, G0148, P3000, P3001, Q0091; and ICD-9 code 91.46), HPV test (CPT codes 87620-87622; CPT code V73.81), colposcopies (CPT codes 56820, 56821, 57420, 57421, 57452, 47454, 57455, 57456, 57460, and 57461), and loop electrosurgical excision procedures (LEEP; CPT codes 57460, 57522, and 57461).